Exclusive Summary

• Offers the world's only oral GLP-1 formulation that overcomes injection compliance barriers, directly targeting an immense blue-ocean market of over 500 million diabetic and 1 billion obese patients globally.
• Possesses highly scarce US-FDA and EU-EMA GMP certifications, enabling Day-1 generic distribution in highly regulated markets and accelerated fast-track registrations in emerging markets.
• Breaks through oral peptide technological barriers and eliminates cold-chain/auto-injector logistics costs, providing distributors with disruptive pricing capabilities and highly lucrative profit margins.